2030 年白蛋白市场预测：按产品类型、应用、最终用户和地区分類的全球分析

根据 Stratistics MRC 的数据，2023 年全球白蛋白市场规模将达到 65 亿美元，预计到 2030 年将达到 103 亿美元，预测期内复合年增长率为 6.7%。

白蛋白是肝臟产生的必需蛋白质，存在于血浆中。它对于人体发生的许多生理过程至关重要。作为载体蛋白，白蛋白在循环中输送多种物质，包括维生素、脂肪酸、荷尔蒙和药物。

根据美国癌症协会的2023年癌症统计数据，预计2023年美国将通报约193万名癌症病例。癌症的高负担预计将增加对 HSA 的需求，从而推动该行业在预测期内的成长。

人口高龄化加剧

随着年龄的增长，人们越来越容易受到各种健康问题的影响，包括慢性病、肝病和需要药物治疗的疾病。低白蛋白血症（一种以血液白蛋白水平低为特征的疾病）在老年人中很常见。因此，对基于白蛋白的治疗和治疗来解决各种医学疾病的需求不断增加。因此，高龄化导致医疗保健成本上升，使得基于白蛋白的治疗方法等先进医疗方法更容易获得，并推动市场扩张。

替代产品和替代品的可得性

白蛋白市场的价格压力可能源自于公司保持竞争力所需的替代品的可用性。因此，我们的白蛋白产品可能会降低报酬率或降低价格，进而影响我们的收益来源。如果白蛋白被接受并且显示出同样有效，医疗保健专业人员和患者可以选择使用替代品或替代品来代替白蛋白。对白蛋白治疗的需求减少可能会影响销售和市场扩张并阻碍市场成长。

生物製药产业的扩张

添加白蛋白可提高药物溶解度、稳定性和生物利用度。白蛋白透过稳定蛋白质并作为药物输送系统来提高生物製药的功效。由于白蛋白具有生物相容性并且能够封装药物，因此它经常用于开发创新的药物输送系统，例如基于奈米颗粒的药物输送系统。人们对生物製药研究和开发的兴趣日益浓厚，导致白蛋白供应商和製药公司之间建立联盟和伙伴关係，推动创新和市场扩张。

製造成本高

精打细算的医院、医疗保健系统和医疗服务提供者可能会犹豫是否要花钱购买昂贵的白蛋白产品。由于生产成本较高，生产白蛋白的製药公司和製造商的报酬率可能较低。我们资助研发和创新以推进基于白蛋白的疗法的能力可能会受到影响，从而抑制市场。

COVID-19 的影响

为了治疗 COVID-19重症患者，在大流行初期，对重症患者监护药物（尤其是白蛋白）的需求增加。在某些情况下，白蛋白被用来补充损失量并为严重患者提供支持性护理。由于与疫情相关的资源重新分配以及对非必要研究活动的限制，一些与白蛋白及其可能用途相关的临床研究和研究计划可能被推迟或中断。

牛血清白蛋白细分市场预计在预测期内规模最大

由于研究、诊断和生物技术行业的高需求，预计牛血清白蛋白细分市场将出现良好的成长。牛血清白蛋白市场服务于各种企业并服务于相对不同的目的。牛血清白蛋白用于生物製药和生物技术领域，并用于製造某些疫苗、医疗设备和生物製药，推动市场成长。

诊断领域预计在预测期内复合年增长率最高

这是因为许多临床测试和测定都会量化白蛋白（一种重要的生物标记），以评估健康和疾病状态。作为完整代谢组的一部分，经常透过肝功能测试和血液检查来评估血清白蛋白水平。非典型白蛋白水平可能表示营养不良、肝臟或肾臟损伤或其他医疗状况。除了定期验血外，白蛋白水平的变化还可用作诊断某些医疗问题的标誌。因此，低白蛋白血症（血清白蛋白水平降低）可能预示着许多疾病，包括肝臟疾病、肾臟疾病、营养不良和发炎疾病。

比最大的地区

北美在预测期内占据最大的市场占有率，因为现代化的医疗设施、长期的医疗基础设施、高医疗保健支出等因素预计将导致该地区在全球白蛋白产业中占据重要的市场地位。此外，北美白蛋白市场受到加拿大卫生署和美国食品药物管理局（FDA）等卫生当局严格的法律规范的监管。遵守监管要求对于产品核可和市场准入至关重要，从而推动市场成长。

复合年增长率最高的地区：

由于医疗领域和白蛋白，特别是人类血清白蛋白（HSA）用于各种治疗目的的频繁使用，预计亚太地区在预测期内将表现出最高的复合年增长率。当地医疗系统使用白蛋白来治疗损伤、肝臟疾病、严重监护、手术和其他疾病。此外，亚太地区的生物製药产业正在显着成长。中国和印度正在成为生物技术和製药行业的主要参与者，支持白蛋白产品的生产和销售。

主要进展：

Aspira 于 2023 年 12 月推出，凭藉在户外休閒领域 30 多年的专业知识和行业洞察力，支持和管理领先的户外休閒活动在线市场 ReserveAmerica®。继续。

2023 年 11 月，美国高品质血浆采集领域的领导者、凯瑞恩生物製药公司 KEDPLASMA 宣布了一个新项目，旨在改善捐赠者体验并提高采集中心的卓越标准。我们很自豪地宣布进行全面整修。

2023 年 11 月，Aspira (TM) 宣布收购了 Astra 和 Campground Manager 软体平台供应商 Mission Management。

提供免费客製化

订阅此报告的客户将收到以下免费自订选项之一：

• 公司简介
  • 其他市场公司的综合分析（最多 3 家公司）
  • 主要企业SWOT分析（最多3家企业）
• 区域分割
  • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
• 竞争基准化分析
  • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

• 概述
• 相关利益者
• 调查范围
• 调查方法
  • 资料探勘
  • 资料分析
  • 资料检验
  • 研究途径
• 调查来源
  • 主要调查来源
  • 二次调查来源
  • 先决条件

第三章市场趋势分析

• 促进因素
• 抑制因素
• 机会
• 威胁
• 产品分析
• 应用分析
• 最终用户分析
• 新兴市场
• 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

• 供应商的议价能力
• 买方议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第五章全球白蛋白市场：依产品类型

• 牛血清白蛋白
• 人血清白蛋白
• 重组白蛋白

第六章全球白蛋白市场：依应用分类

• 药物输送
• 疫苗
• 诊断
• 体外受精
• 医疗设备涂层
• 介质和稳定剂
• 其他用途

第七章 全球白蛋白市场：依最终使用者分类

• 研究机构
• 製药和生物技术公司
• 医院
• 其他最终用户

第八章全球白蛋白市场：按地区

• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 纽西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地区
• 中东/非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 卡达
  • 南非
  • 其他中东/非洲

第九章 主要进展

• 合约、伙伴关係、协作和合资企业
• 收购和合併
• 新产品发布
• 业务扩展
• 其他关键策略

第十章 公司简介

• Kedrion SpA
• Lazuline Bio
• Albumin Bioscience
• Aspira Chemical
• ALBUMEDIX
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Cyagen Biosciences
• CSL Behring（CSL）
• Takeda Pharmaceutical Company Limited
• InVitria
• Grifols, SA
• Biorbyt Ltd.
• Octapharma AG
• Akron Biotech
• Novozymes AS
• China Biologic Products Holdings Inc.
• Baxter International Inc.
• Bristol-Myers Squibb Company
• Medxbio Pte Ltd

According to Stratistics MRC, the Global Albumin Market is accounted for $6.5 billion in 2023 and is expected to reach $10.3 billion by 2030 growing at a CAGR of 6.7% during the forecast period. A necessary protein produced by the liver, albumin is present in blood plasma. It is essential to many physiological processes that occur in the human body. As a carrier protein, albumin moves different materials throughout the circulation, including vitamins, fatty acids, hormones, and medications.

According to the American Cancer Society 2023 Cancer Statistics, about 1.93 million cancer cases are estimated to be reported in 2023 in the United States. The high burden of cancer is expected to augment the demand for HSA, thereby boosting segment growth over the forecast period.

Market Dynamics:

Driver:

Growing aging population

People are increasingly vulnerable as they become older to a variety of health problems, including chronic diseases, liver disease, and ailments that need to be treated with medicine. Among elderly persons, hypoalbuminemia a disorder marked by low blood levels of albumin is common. As a result, there is an increased need for therapies and treatments based on albumin to address various medical disorders. Thus the aging population is linked to rising healthcare costs, which in turn makes sophisticated medical treatments like albumin-based therapies more accessible, which fuels market expansion.

Restraint:

Availability of substitute products and alternatives

Price pressure in the albumin market might result from the availability of substitute goods, as businesses aim to maintain their competitiveness. This may lead to lower profit margins or price reductions for goods based on albumin, which would impact revenue streams. Healthcare professionals and patients may choose to use replacement goods or alternatives in place of albumin if they are accepted and show equivalent efficacy. Sales and market expansion may be impacted by this decline in the demand for albumin-based treatments thus hampering the growth of the market.

Opportunity:

Expanding biopharmaceutical industry

Pharmaceutical goods are formulated with albumin to increase the medications' solubility, stability, and bioavailability. It improves the effectiveness of biopharmaceuticals by stabilizing proteins and serving as a medication delivery system. Because albumin is biocompatible and can encapsulate medications, it is frequently used in the development of innovative drug delivery systems, such as those based on nanoparticles. Growing interest in biopharmaceutical R&D leads to alliances and partnerships between albumin suppliers and pharmaceutical firms, which promotes innovation and market expansion.

Threat:

High cost of production

Budget-conscious hospitals, healthcare systems, and providers could be hesitant to spend money on pricey albumin products, which would restrict utilization or make people, choose less costly options. Due to the high manufacturing costs, pharmaceutical businesses or manufacturers who produce albumin may see a decrease in their profit margins. Their capacity to fund R&D and innovation to advance albumin-based therapy may be impacted by this thereby impeding the market.

COVID-19 Impact

In order to treat severe COVID-19 patients, there was an increase in demand for critical care treatments during the early stages of the pandemic, particularly albumin. In several instances, albumin was utilized to replenish lost volume and provide supportive care for patients in severe condition. The pandemic-related resource reallocation and limitations on non-essential research activities may have caused several clinical studies and research projects pertaining to albumin or its possible uses to be postponed or interrupted.

The bovine serum albumin segment is expected to be the largest during the forecast period

The bovine serum albumin segment is estimated to have a lucrative growth, due to larger demands of the research, diagnostics, and biotechnology industries, human serum albumin (HSA) is predominantly employed for therapeutic purposes in the healthcare industry. The marketplaces for bovine serum albumin serve various businesses and serve relatively different goals. The biopharmaceutical and biotechnology sectors both use bovine serum albumin and it is employed in the creation and manufacturing of specific vaccinations, medical devices, and biologic medications thus encouraging the growth of the market.

The diagnostics segment is expected to have the highest CAGR during the forecast period

The diagnostics segment is anticipated to witness the highest CAGR growth during the forecast period, because in order to evaluate health and disease states, a number of clinical tests and assays quantify albumin, a critical biomarker. Serum albumin levels are frequently assessed in blood tests as part of liver function tests or full metabolic panels. Atypical albumin levels may suggest malnourishment, disorders of the liver or kidneys, or other medical conditions. Changes in albumin levels can be used as markers to diagnose certain medical problems in addition to regular blood testing. Thus hypoalbuminemia, or low serum albumin levels, can indicate a number of illnesses, including liver disease, renal problems, malnourishment, and inflammatory diseases.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the North America's modern medical facilities, long-standing healthcare infrastructure, and high healthcare spending all contribute to the region's significant market position in the worldwide albumin industry. Additionally, strict regulatory frameworks set by health agencies like Health Canada and the U.S. Food and Drug Administration (FDA) govern the albumin market in North America. Adherence to regulatory requirements is crucial for both product approvals and market access boosts the growth of the market.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the medical field, albumin particularly human serum albumin (HSA) that is frequently utilized for a range of therapeutic purposes. Albumin is used by the medical systems in the area to treat injuries, liver illnesses, critical care, operations, and other ailments. Moreover, the biopharmaceutical sector has grown significantly in the Asia Pacific area. China and India are becoming as major actors in the biotechnology and pharmaceutical industries, helping to produce and market goods based on albumin.

Key players in the market:

Some of the key players profiled in the Albumin Market include Kedrion S.p.A., Lazuline Bio, Albumin Bioscience, Aspira Chemical, ALBUMEDIX, Merck KGaA, Thermo Fisher Scientific Inc., Cyagen Biosciences, CSL Behring (CSL), Takeda Pharmaceutical Company Limited, InVitria, Grifols, S.A., Biorbyt Ltd., Octapharma AG, Akron Biotech, Novozymes AS, China Biologic Products Holdings Inc., Baxter International Inc., Bristol-Myers Squibb Company and Medxbio Pte Ltd

Key Developments:

In December 2023, Aspira Launches with More Than 30 Years of Expertise and Industry Insight in the Outdoor Recreation Space and the company will continue to support and manage ReserveAmerica®, the renowned online marketplace for outdoor recreation activities

In November 2023, KEDPLASMA, a Kedrion Biopharma company and a leader in the US in the collection of high-quality plasma, is proud to announce a comprehensive remodeling initiative aimed at enhancing the experience of its donors and raising the standard of excellence in its collection centers.

In November 2023, Aspira™ announced that it has acquired Mission Management, provider of the Astra and Campground Manager software platforms.

Product Types Covered:

• Bovine Serum Albumin
• Human Serum Albumin
• Recombinant Albumin

Applications Covered:

• Drug Delivery
• Vaccines
• Diagnostics
• In Vitro Fertilization
• Medical Device Coating
• Culture Medium & Stabilizer
• Other Applications

End Users Covered:

• Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Albumin Market, By Product Type

• 5.1 Introduction
• 5.2 Bovine Serum Albumin
• 5.3 Human Serum Albumin
• 5.4 Recombinant Albumin

6 Global Albumin Market, By Application

• 6.1 Introduction
• 6.2 Drug Delivery
• 6.3 Vaccines
• 6.4 Diagnostics
• 6.5 In Vitro Fertilization
• 6.6 Medical Device Coating
• 6.7 Culture Medium & Stabilizer
• 6.8 Other Applications

7 Global Albumin Market, By End User

• 7.1 Introduction
• 7.2 Research Institutes
• 7.3 Pharmaceutical & Biotechnology Companies
• 7.4 Hospitals
• 7.5 Other End Users

8 Global Albumin Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Kedrion S.p.A.
• 10.2 Lazuline Bio
• 10.3 Albumin Bioscience
• 10.4 Aspira Chemical
• 10.5 ALBUMEDIX
• 10.6 Merck KGaA
• 10.7 Thermo Fisher Scientific Inc.
• 10.8 Cyagen Biosciences
• 10.9 CSL Behring (CSL)
• 10.10 Takeda Pharmaceutical Company Limited
• 10.11 InVitria
• 10.12 Grifols, S.A.
• 10.13 Biorbyt Ltd.
• 10.14 Octapharma AG
• 10.15 Akron Biotech
• 10.16 Novozymes AS
• 10.17 China Biologic Products Holdings Inc.
• 10.18 Baxter International Inc.
• 10.19 Bristol-Myers Squibb Company
• 10.20 Medxbio Pte Ltd

List of Tables

• Table 1 Global Albumin Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Albumin Market Outlook, By Product Type (2021-2030) ($MN)
• Table 3 Global Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
• Table 4 Global Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
• Table 5 Global Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
• Table 6 Global Albumin Market Outlook, By Application (2021-2030) ($MN)
• Table 7 Global Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 8 Global Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
• Table 9 Global Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 10 Global Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
• Table 11 Global Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
• Table 12 Global Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
• Table 13 Global Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 14 Global Albumin Market Outlook, By End User (2021-2030) ($MN)
• Table 15 Global Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 16 Global Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 17 Global Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 18 Global Albumin Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 19 North America Albumin Market Outlook, By Country (2021-2030) ($MN)
• Table 20 North America Albumin Market Outlook, By Product Type (2021-2030) ($MN)
• Table 21 North America Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
• Table 22 North America Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
• Table 23 North America Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
• Table 24 North America Albumin Market Outlook, By Application (2021-2030) ($MN)
• Table 25 North America Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 26 North America Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
• Table 27 North America Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 28 North America Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
• Table 29 North America Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
• Table 30 North America Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
• Table 31 North America Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 32 North America Albumin Market Outlook, By End User (2021-2030) ($MN)
• Table 33 North America Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 34 North America Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 35 North America Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 36 North America Albumin Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 37 Europe Albumin Market Outlook, By Country (2021-2030) ($MN)
• Table 38 Europe Albumin Market Outlook, By Product Type (2021-2030) ($MN)
• Table 39 Europe Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
• Table 40 Europe Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
• Table 41 Europe Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
• Table 42 Europe Albumin Market Outlook, By Application (2021-2030) ($MN)
• Table 43 Europe Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 44 Europe Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
• Table 45 Europe Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 46 Europe Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
• Table 47 Europe Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
• Table 48 Europe Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
• Table 49 Europe Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 50 Europe Albumin Market Outlook, By End User (2021-2030) ($MN)
• Table 51 Europe Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 52 Europe Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 53 Europe Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 54 Europe Albumin Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 55 Asia Pacific Albumin Market Outlook, By Country (2021-2030) ($MN)
• Table 56 Asia Pacific Albumin Market Outlook, By Product Type (2021-2030) ($MN)
• Table 57 Asia Pacific Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
• Table 58 Asia Pacific Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
• Table 59 Asia Pacific Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
• Table 60 Asia Pacific Albumin Market Outlook, By Application (2021-2030) ($MN)
• Table 61 Asia Pacific Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 62 Asia Pacific Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
• Table 63 Asia Pacific Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 64 Asia Pacific Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
• Table 65 Asia Pacific Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
• Table 66 Asia Pacific Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
• Table 67 Asia Pacific Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 68 Asia Pacific Albumin Market Outlook, By End User (2021-2030) ($MN)
• Table 69 Asia Pacific Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 70 Asia Pacific Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 71 Asia Pacific Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 72 Asia Pacific Albumin Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 73 South America Albumin Market Outlook, By Country (2021-2030) ($MN)
• Table 74 South America Albumin Market Outlook, By Product Type (2021-2030) ($MN)
• Table 75 South America Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
• Table 76 South America Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
• Table 77 South America Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
• Table 78 South America Albumin Market Outlook, By Application (2021-2030) ($MN)
• Table 79 South America Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 80 South America Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
• Table 81 South America Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 82 South America Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
• Table 83 South America Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
• Table 84 South America Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
• Table 85 South America Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 86 South America Albumin Market Outlook, By End User (2021-2030) ($MN)
• Table 87 South America Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 88 South America Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 89 South America Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 90 South America Albumin Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 91 Middle East & Africa Albumin Market Outlook, By Country (2021-2030) ($MN)
• Table 92 Middle East & Africa Albumin Market Outlook, By Product Type (2021-2030) ($MN)
• Table 93 Middle East & Africa Albumin Market Outlook, By Bovine Serum Albumin (2021-2030) ($MN)
• Table 94 Middle East & Africa Albumin Market Outlook, By Human Serum Albumin (2021-2030) ($MN)
• Table 95 Middle East & Africa Albumin Market Outlook, By Recombinant Albumin (2021-2030) ($MN)
• Table 96 Middle East & Africa Albumin Market Outlook, By Application (2021-2030) ($MN)
• Table 97 Middle East & Africa Albumin Market Outlook, By Drug Delivery (2021-2030) ($MN)
• Table 98 Middle East & Africa Albumin Market Outlook, By Vaccines (2021-2030) ($MN)
• Table 99 Middle East & Africa Albumin Market Outlook, By Diagnostics (2021-2030) ($MN)
• Table 100 Middle East & Africa Albumin Market Outlook, By In Vitro Fertilization (2021-2030) ($MN)
• Table 101 Middle East & Africa Albumin Market Outlook, By Medical Device Coating (2021-2030) ($MN)
• Table 102 Middle East & Africa Albumin Market Outlook, By Culture Medium & Stabilizer (2021-2030) ($MN)
• Table 103 Middle East & Africa Albumin Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 104 Middle East & Africa Albumin Market Outlook, By End User (2021-2030) ($MN)
• Table 105 Middle East & Africa Albumin Market Outlook, By Research Institutes (2021-2030) ($MN)
• Table 106 Middle East & Africa Albumin Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
• Table 107 Middle East & Africa Albumin Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 108 Middle East & Africa Albumin Market Outlook, By Other End Users (2021-2030) ($MN)